Roivant Sciences Ltd

Roivant insider sales reveal cautious valuation signals—an insider sold 160k shares at $27.70, hinting at future funding moves while the stock’s P/E stays negative.

Roivant Sciences CEO’s March 30, 2026 insider trade: CVAR conversion, share sales, and liquidity strategy—insider confidence signals a cautious but optimistic outlook.

Roivant’s CEO converts CVARs into 97k shares, signaling insider confidence and potential upside amid a $18B market cap.

Insider trading by Fitzgerald Meghan at Roivant shows a “buy low, sell high” pattern tied to positive Phase 3 brepocitinib data, hinting at a short‑term rally.

Fitzgerald Meghan’s quick buy‑sell moves on Roivant’s stock reveal a short‑term profit strategy, signaling insider caution amid a promising but volatile biotech outlook.

Roivant insider selling: Jennifer Humes’ tax‑planned RSU liquidation and its implications for investor confidence.

Insight into Roivant’s insider sales: Melissa Epperly’s March trade shows systematic liquidity moves, yet the company’s 153 % YTD rally and strong pipeline keep long‑term growth on track.

Insider sales at Roivant hint at liquidity concerns and potential market shift – a must‑watch for investors on upcoming earnings and clinical milestones.

Insider Mayukh’s $12.68 buy of 651k Roivant shares shows confidence in its pipeline but isn’t a clear “buy” signal—watch sentiment and future filings for clues.

Insider activity at Roivant Sciences shows non‑employee director Momtazee James C boosting his holdings, signaling confidence in the biotech firm’s future and a potential short‑term rally for shareholders.